Prof Marija Krstic-Demonacos' Outputs (7)

Insight into glucocorticoid receptor signalling through interactome model analysis (2017)
Journal Article
Bakker, E., Tian, K., Mutti, L., Demonacos, C., Schwartz, J., & Krstic-Demonacos, M. (2017). Insight into glucocorticoid receptor signalling through interactome model analysis. PLoS Computational Biology, 13(11), https://doi.org/10.1371/journal.pcbi.1005825

Glucocorticoid hormones (GCs) are used to treat a variety of diseases because of their potent anti-inflammatory effect and their ability to induce apoptosis in lymphoid malignancies through the glucocorticoid receptor (GR). Despite ongoing research,... Read More about Insight into glucocorticoid receptor signalling through interactome model analysis.

Immunotherapy advances for mesothelioma treatment (2017)
Journal Article

Introduction: Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure. Despite application of different modalities such as chemotherapy, radiotherapy and surgery, patient prognosis remains very poor and therapies are ineffect... Read More about Immunotherapy advances for mesothelioma treatment.

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Tian, K., Demonacos, C., Krstic- Demonacos, M., & Mutti, L. (2017). Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Expert Opinion on Investigational Drugs, 26(8), 933-944. https://doi.org/10.1080/13543784.2017.1351545

Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to poor prognosis. Within... Read More about Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia (2017)
Journal Article

Glucocorticoids (GCs) and topoisomerase II inhibitors are used to treat acute lymphoblastic leukaemia (ALL) as they induce death in lymphoid cells through the glucocorticoid receptor (GR) and p53 respectively. Mechanisms underlying ALL cell death and... Read More about Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.

Current and prospective pharmacotherapies for the treatment of pleural mesothelioma (2017)
Journal Article

Introduction: Mesothelioma is a rare asbestos-linked cancer with an expected incidence peak between 2015–2030. Therapies remain ineffective, thus developing and testing novel treatments is important for both oncologists and researchers.


Areas co... Read More about Current and prospective pharmacotherapies for the treatment of pleural mesothelioma.

Anti-CTLA-4 therapy for malignant mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy, 9(3), 273-280. https://doi.org/10.2217/imt-2016-0123

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This... Read More about Anti-CTLA-4 therapy for malignant mesothelioma.

miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway (2017)
Journal Article
peptides, by targeting CXCR4-p21 pathway. BMC Cancer, 17, 33-43. https://doi.org/10.1186/s12885-016-3003-9

Abstract
Background: Antimicrobial peptides (AMPs) play important roles in the innate immune system of all life forms and
recently have been characterized as multifunctional peptides that have a variety of biological roles such as anticancer
agent... Read More about miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway.